Eagle Pharmaceuticals is emerging from the pandemic in solid shape. The Woodcliff Lake-based company boasts a robust pipeline and just added two commercialized products through its acquisition of Acacia Pharma. In short, Eagle is ready to soar.
So what’s next? NJBIZ recently spoke with Scott Tarriff, the company’s founder, president and CEO, about Eagle’s recent acquisition of Acacia Pharma, how the business operated over the past several years and why he thinks continued success is in the cards.
“Fortunately for us, if you just look at the way we run our business over the last five or six years, we’ve been highly profitable relative to our size. We’ve generated a lot of cash, we’ve put it in the bank. We bought back our stock. And so we don’t have debt to worry about,” Tarriff said. “We don’t have anything holding us down that we really had to be concerned about. Maybe we made a little bit less money. And maybe our stock is down a little bit more than we would like it to be. But at the end of the day, we’re right in the middle of launching two significant products.”
And those factors all bode well for the future. “We’re generating a lot of revenue and profit from those,” he said. “We’re in a position where cash is probably very important. We don’t need to raise money. We’re building cash every day. And so we’re in a great situation.”